Evommune, Inc. (New York Stock Exchange:EVMN)
| Market Cap | 215.21M-70.7% |
| Revenue (ttm) | 10.00M+233.3% |
| Net Income | -94.67M-28.2% |
| EPS | -2.83-14.6% |
| Shares Out | 36.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 579,084 |
| Open | 5.90 |
| Previous Close | 5.77 |
| Day's Range | 5.81 - 6.00 |
| 52-Week Range | 5.64 - 33.20 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 25.00(+321.59%) |
| Earnings Date | Oct 16, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About EVMN
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
$EVMN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in EVMN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EVMN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EVMN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EVMN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EVMN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EVMN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $6.10M |
| IWMiShares Russell 2000 ETF | $2.33M |
| VXFVanguard Extended Market ETF | $2.06M |
| FESMFidelity Enhanced Small Cap ETF | $883.11K |
| IWOiShares Russell 2000 Growth ETF | $830.03K |
| VTWOVanguard Russell 2000 ETF | $738.02K |
Estimated from each fund’s disclosed top holdings × AUM
EVMN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EVMN’s recent data — informational, not investment advice